Curanex Pharmaceuticals Inc (NASDAQ:CURX – Get Free Report)’s stock price crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $4.94 and traded as low as $4.59. Curanex Pharmaceuticals shares last traded at $4.8340, with a volume of 6,252 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a research note on Tuesday, October 27th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.
View Our Latest Research Report on Curanex Pharmaceuticals
Curanex Pharmaceuticals Price Performance
The firm’s 50 day simple moving average is $4.94 and its 200-day simple moving average is $6.09.
Curanex Pharmaceuticals (NASDAQ:CURX – Get Free Report) last posted its quarterly earnings results on Friday, November 13th. The company reported ($1.86) EPS for the quarter.
Curanex Pharmaceuticals Company Profile
Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.
See Also
- Five stocks we like better than Curanex Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Curanex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curanex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
